<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">9216904</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">2419</journal-id>
      <journal-id journal-id-type="nlm-ta">Nat Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat. Genet.</journal-id>
      <journal-title-group>
        <journal-title>Nature genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1061-4036</issn>
      <issn pub-type="epub">1546-1718</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">30455415</article-id>
      <article-id pub-id-type="pmc">6309588</article-id>
      <article-id pub-id-type="doi">10.1038/s41588-018-0265-y</article-id>
      <article-id pub-id-type="manuscript">HHMIMS1508198</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>ROBO4</italic> Variants Predispose Individuals to Bicuspid
Aortic Valve and Thoracic Aortic Aneurysm</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Gould</surname>
            <given-names>Russell A</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Aziz</surname>
            <given-names>Hamza</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Woods</surname>
            <given-names>Courtney E</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Seman-Senderos</surname>
            <given-names>Manuel Alejandro</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sparks</surname>
            <given-names>Elizabeth</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Preuss</surname>
            <given-names>Christoph</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>W&#xFC;nnemann</surname>
            <given-names>Florian</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bedja</surname>
            <given-names>Djahida</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moats</surname>
            <given-names>Cassandra R</given-names>
          </name>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McClymont</surname>
            <given-names>Sarah A</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rose</surname>
            <given-names>Rebecca</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sobeira</surname>
            <given-names>Nara</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ling</surname>
            <given-names>Hua</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MacCarrick</surname>
            <given-names>Gretchen</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Anand Kumar</surname>
            <given-names>Ajay</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Luyckx</surname>
            <given-names>Ilse</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cannaerts</surname>
            <given-names>Elyssa</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Verstraeten</surname>
            <given-names>Aline</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bj&#xF6;rk</surname>
            <given-names>Hanna M</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lehsau</surname>
            <given-names>Ann-Cathrin</given-names>
          </name>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jaskula-Ranga</surname>
            <given-names>Vinod</given-names>
          </name>
          <xref ref-type="aff" rid="A12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lauridsen</surname>
            <given-names>Henrik</given-names>
          </name>
          <xref ref-type="aff" rid="A13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shah</surname>
            <given-names>Asad A</given-names>
          </name>
          <xref ref-type="aff" rid="A14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bennett</surname>
            <given-names>Christopher L</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ellinor</surname>
            <given-names>Patrick T</given-names>
          </name>
          <xref ref-type="aff" rid="A15">15</xref>
          <xref ref-type="aff" rid="A16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lin</surname>
            <given-names>Honghuang</given-names>
          </name>
          <xref ref-type="aff" rid="A17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Isselbacher</surname>
            <given-names>Eric M</given-names>
          </name>
          <xref ref-type="aff" rid="A18">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cardenas</surname>
            <given-names>Christian Lacks Lino</given-names>
          </name>
          <xref ref-type="aff" rid="A19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Butcher</surname>
            <given-names>Jonathan T</given-names>
          </name>
          <xref ref-type="aff" rid="A13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hughes</surname>
            <given-names>G. Chad</given-names>
          </name>
          <xref ref-type="aff" rid="A20">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lindsay</surname>
            <given-names>Mark E.</given-names>
          </name>
          <xref ref-type="aff" rid="A21">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <collab>Center for Mendelian Genomics</collab>
          <xref ref-type="aff" rid="A22">22</xref>
        </contrib>
        <contrib contrib-type="author">
          <collab>MIBAVA Leducq Consortium</collab>
          <xref ref-type="aff" rid="A22">22</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mertens</surname>
            <given-names>Luc</given-names>
          </name>
          <xref ref-type="aff" rid="A23">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Franco-Cereceda</surname>
            <given-names>Anders</given-names>
          </name>
          <xref ref-type="aff" rid="A24">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Verhagen</surname>
            <given-names>Judith MA</given-names>
          </name>
          <xref ref-type="aff" rid="A25">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wessels</surname>
            <given-names>Marja</given-names>
          </name>
          <xref ref-type="aff" rid="A26">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mohamed</surname>
            <given-names>Salah A</given-names>
          </name>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Per</surname>
            <given-names>Eriksson</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mital</surname>
            <given-names>Seema</given-names>
          </name>
          <xref ref-type="aff" rid="A26">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Laer</surname>
            <given-names>Lut Van</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Loeys</surname>
            <given-names>Bart L</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
          <xref ref-type="aff" rid="A27">27</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Andelfinger</surname>
            <given-names>Gregor</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A28">28</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McCallion</surname>
            <given-names>Andrew S</given-names>
          </name>
          <xref rid="CR1" ref-type="corresp">#</xref>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A5">5</xref>
          <xref ref-type="aff" rid="A30">30</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dietz</surname>
            <given-names>Harry C</given-names>
          </name>
          <xref rid="CR1" ref-type="corresp">#</xref>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A29">29</xref>
          <xref ref-type="aff" rid="A30">30</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>McKusick-Nathans Institute of Genetic Medicine, Johns
Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
      <aff id="A2"><label>2</label>Howard Hughes Medical Institute, Baltimore, Maryland,
USA</aff>
      <aff id="A3"><label>3</label>Cardiovascular Genetics, Department of Pediatrics, Centre
Hospitalier Universitaire Sainte-Justine Research Centre, Universit&#xE9; de
Montr&#xE9;al, Montreal, Quebec, Canada</aff>
      <aff id="A4"><label>4</label>The Jackson Laboratory, Bar Harbor, Maine, USA</aff>
      <aff id="A5"><label>5</label>Department of Molecular and Comparative Pathobiology, Johns
Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
      <aff id="A6"><label>6</label>Heart and Vascular Institute, Division of Cardiology, Johns
Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
      <aff id="A7"><label>7</label>Oregon National Primate Research Center, Portland, Oregon,
USA</aff>
      <aff id="A8"><label>8</label>Center for Inherited Disease Research, Johns Hopkins
University School of Medicine, Baltimore, Maryland, USA</aff>
      <aff id="A9"><label>9</label>Center for Medical Genetics, Faculty of Medicine and Health
Sciences, Antwerp University Hospital and University of Antwerp, Antwerp,
Belgium</aff>
      <aff id="A10"><label>10</label>Center for Molecular Medicine, Department of Medicine
Solna, University hospital Solna, Karolinska Institutet, Stockholm, Sweden</aff>
      <aff id="A11"><label>11</label>Department of Cardiac and Thoracic Vascular Surgery,
University Hospital L&#xFC;beck, L&#xFC;beck, Germany</aff>
      <aff id="A12"><label>12</label>Wilmer Eye Institute in the Department of Ophthalmology
at the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</aff>
      <aff id="A13"><label>13</label>The Nancy E. and Peter C. Meinig School of Biomedical
Engineering, Cornell University, Ithaca, New York</aff>
      <aff id="A14"><label>14</label>Rex Hospital, Raleigh, North Carolina</aff>
      <aff id="A15"><label>15</label>The Broad Institute of MIT and Harvard, Cambridge, MA,
USA</aff>
      <aff id="A16"><label>16</label>Cardiovascular Research Institute, Massachussets General
Hospital, Charlestown, MA, USA</aff>
      <aff id="A17"><label>17</label>Section of Computational Biomedicine, Department of
Medicine, Boston University School of Medicine, Boston, MA, USA</aff>
      <aff id="A18"><label>18</label>Thoracic Aortic Center, Division of Cardiology,
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA</aff>
      <aff id="A19"><label>19</label>Cardiovascular Research Center, Division of Cardiology,
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA</aff>
      <aff id="A20"><label>20</label>Division of Cardiovascular and Thoracic Surgery, Duke
University Medical Center, Durham, North Carolina</aff>
      <aff id="A21"><label>21</label>Thoracic Aortic Center and Cardiovascular Genetics
Program, Division of Cardiology, Massachusetts General Hospital, Harvard Medical
School, Boston, MA, USA</aff>
      <aff id="A22"><label>22</label>A list of members of affiliations appears at the end of
the paper</aff>
      <aff id="A23"><label>23</label>Division of Cardiology, The Hospital for Sick Children,
Labatt Family Heart Centre, Toronto, Ontario, Canada</aff>
      <aff id="A24"><label>24</label>Department of Molecular Medicine and Surgery, University
Hospital Solna, Karolinska Institutet, Stockholm, Sweden</aff>
      <aff id="A25"><label>25</label>Department of Clinical Genetics, Erasmus MC, University
Medical Center Rotterdam, Rotterdam, The Netherlands</aff>
      <aff id="A26"><label>26</label>Department of Pediatrics, Hospital for Sick Children,
University of Toronto, Toronto, Ontario, Canada</aff>
      <aff id="A27"><label>27</label>Department of Human Genetics, Radboud University Medical
Centre, Nijmegen, The Netherlands</aff>
      <aff id="A28"><label>28</label>Department of Pediatrics, Universit&#xE9; de
Montr&#xE9;al, Montreal, Quebec, Canada</aff>
      <aff id="A29"><label>29</label>Department of Pediatrics, Division of Pediatric
Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland,
USA</aff>
      <aff id="A30"><label>30</label>Department of Medicine, Johns Hopkins University School
of Medicine, Baltimore, Maryland, USA</aff>
      <author-notes>
        <fn fn-type="con" id="FN1">
          <p id="P1">AUTHOR CONTRIBUTIONS</p>
          <p id="P2">H.C.D., B.L.L., G.A., and the MIBAVA Leducq Consortium recruited
participants for the study. A.S.M., H.C.D., G.A., and B.L.L. were
instrumental in the experimental design and interpretation of the data.
R.A.G. and M.A.S.S. performed in vitro experiments and R.A.G. performed
mouse experiments with assistance from D.B. under the supervision of H.C.D.
C.E.W. performed all zebrafish experiments with assistance from C.R.M.,
R.R., and S.A.M. under the supervision of A.S.M. The initial mouse studies,
genetic analysis, and identification of the gene of interest were performed
by H.A. under the supervision of H.C.D.</p>
        </fn>
        <corresp id="CR1"><label>#</label>Denotes equal co-corresponding author</corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>11</day>
        <month>10</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>11</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>19</day>
        <month>5</month>
        <year>2019</year>
      </pub-date>
      <volume>51</volume>
      <issue>1</issue>
      <fpage>42</fpage>
      <lpage>50</lpage>
      <!--elocation-id from pubmed: 10.1038/s41588-018-0265-y-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, and download text and data-mine the
content in such documents, for the purposes of academic research, subject
always to the full Conditions of use:<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
      </permissions>
      <abstract id="ABS1">
        <p id="P3">Bicuspid aortic valve (BAV) is a common congenital heart defect
(population incidence, 1&#x2013;2%)<sup><xref rid="R1" ref-type="bibr">1</xref>&#x2013;<xref rid="R3" ref-type="bibr">3</xref></sup> that
frequently presents with ascending aortic aneurysm (AscAA)<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. BAV/AscAA shows autosomal dominant
inheritance with incomplete penetrance and male predominance. Causative gene
mutations are known for &#x2264;1% of nonsyndromic BAV cases with/without AscAA
(e.g. <italic>NOTCH1</italic>, <italic>SMAD6</italic>)<sup><xref rid="R5" ref-type="bibr">5</xref>&#x2013;<xref rid="R8" ref-type="bibr">8</xref></sup>, impeding mechanistic insight and development of therapeutic
strategies. We report the identification of mutations in <italic>ROBO4</italic>,
encoding a factor known to contribute to endothelial performance, that segregate
with disease in two families. Targeted sequencing of <italic>ROBO4</italic>
revealed enrichment for rare variants in BAV/AscAA probands compared to
controls. Targeted silencing of <italic>ROBO4</italic> or mutant ROBO4
expression in endothelial cell lines results in impaired barrier function and a
synthetic repertoire suggestive of endothelial-to-mesenchymal transition (EnMT);
concordant BAV/AscAA-associated findings are observed in patients and animal
models deficient for ROBO4. These data identify a novel endothelial etiology for
this common human disease phenotype.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p id="P4">Kindreds segregating BAV/AscAA often exhibit wide variation in cardiovascular
manifestations between affected individuals, including complete non-penetrance (skewed
toward females), isolated BAV, isolated AscAA, and variable location of the site of
ascending aortic dilatation including isolated aortic root aneurysm (i.e. at the sinuses
of Valsalva, AoRA), or more distal ascending aortic aneurysm (DAscAA; collectively
AscAA)<sup><xref rid="R9" ref-type="bibr">9</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref></sup>. This observation suggests that BAV and AscAA
are both variably penetrant primary manifestations of the same underlying gene
defect(s). While enrichment for BAV can be seen in syndromic presentations of thoracic
aortic aneurysm (e.g. Loeys-Dietz syndrome caused by mutations in genes encoding primary
effectors of the transforming growth factor-&#x3B2; (TGF&#x3B2;) signaling pathway),
isolated DAscAA is exceedingly rare in these conditions suggesting a mechanistic
distinction for nonsyndromic BAV/AscAA<sup><xref rid="R13" ref-type="bibr">13</xref>&#x2013;<xref rid="R15" ref-type="bibr">15</xref></sup>. The genetic
etiology and molecular pathogenesis of nonsyndromic BAV/AscAA remains largely elusive
despite intensive effort. Likely obstacles to progress include extreme locus
heterogeneity and the confounding influence of incomplete penetrance, sex bias, and
environmental and/or genetic modification of disease onset and severity. In this study,
we sought to identify genes responsible for nonsyndromic BAV/AscAA using whole exome
sequencing (WES) and a familial segregation approach.</p>
    <p id="P5">A total of nine patient families (<xref rid="F1" ref-type="fig">Fig. 1a,c</xref>
and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 1</xref>), 286
individual probands, and 193 unrelated controls without structural heart disease were
enrolled in our WES initiative. In one large family (Family 1), eight individuals showed
AoRA with or without DAscAA; two had associated BAV (<xref rid="F1" ref-type="fig">Fig.
1a</xref>).</p>
    <p id="P6">Initial sequencing of a panel of genes implicated in familial thoracic aortic
aneurysm (<italic>ACTA2</italic>, <italic>FBN1</italic>, <italic>MYH11</italic>,
<italic>MYLK</italic>, <italic>SMAD3</italic>, <italic>TGFBR1/2</italic>)<sup><xref rid="R16" ref-type="bibr">16</xref>&#x2013;<xref rid="R21" ref-type="bibr">21</xref></sup> identified no mutations. WES in five affecteds of family 1
identified a novel heterozygous mutation at the splice acceptor site of
<italic>ROBO4</italic> exon 13 (g.124757628C&gt;A, c.2056+1G&gt;T, denoting
the variant position in genomic DNA and complementary DNA, respectively. NC_000011.9 and
NM_019055.5) (<xref rid="F1" ref-type="fig">Fig. 1a</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2a</xref>). We confirmed that
all eight affected family members carried the mutation. Interestingly, seven of eight
affected individuals were male including both with BAV. Two clinically unaffected female
family members were heterozygous for the <italic>ROBO4</italic> splice-site mutation.
Pathology from one family member with BAV revealed valve thickening in association with
a pronounced fibroproliferative process (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2b</xref>). Amplification and
sequencing of cDNA derived from patient and control fibroblasts showed that the
splice-site mutation results in the skipping of the 108 base pairs encoding exon 13 of
<italic>ROBO4</italic>, resulting in an in-frame transcript encoding a protein
isoform missing 36 amino acids from the intracellular domain (<xref rid="F1" ref-type="fig">Fig. 1b</xref>). In family 2, WES revealed a heterozygous
<italic>ROBO4</italic> missense variant (c.190C&gt;T; p.Arg64Cys) in a woman,
with atrial septal defect (ASD) and aortic valve stenosis (AVS) that required surgery,
and her son with ASD, BAV and significant AVS (<xref rid="F1" ref-type="fig">Fig.
1c</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig.
2c</xref>). This variant is exceedingly rare (ExAC frequency: 19/98,998), predicted
deleterious by Polyphen and SIFT, and predicted to be among the 1% most deleterious
substitutions possible in the human genome by the Combined Annotation Dependent
Depletion (CADD) algorithm (score, 21.6). The mutation substitutes an evolutionarily
conserved residue in the Ig-like C2-type 1 extracellular domain of ROBO4. Of the
additional 286 individual probands evaluated, four variants (p.Ala95Thr, p.Thr232Met,
p.His411Gln and p.Arg568Ter) met our <italic>a priori</italic> filter, restricting our
focus to exceedingly rare (MAF&lt;0.01%), or rare and predicted highly deleterious
(MAF&lt;0.1% and CADD&gt;20) variants (<xref rid="F1" ref-type="fig">Fig.
1d</xref> and <xref rid="T1" ref-type="table">Table 1</xref>). All four were
confirmed by Sanger sequencing.</p>
    <p id="P7">We then sequenced an additional 441 probands with BAV/AscAA and 183 unrelated
controls, with echocardiogram-confirmed absence of structural cardiovascular disease,
for <italic>ROBO4</italic> mutations using the Haloplex target enrichment system (99.47%
of <italic>ROBO4</italic> base positions &#x2265;10x coverage in 90% of samples). Seven
additional BAV/AscAA probands harbored heterozygous <italic>ROBO4</italic> variants that
fulfilled filtering criteria, including five missense mutations and one frameshift
mutation (<xref rid="F1" ref-type="fig">Fig. 1d</xref> and <xref rid="T1" ref-type="table">Table 1</xref>; See <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 1</xref> for corresponding
clinical data).</p>
    <p id="P8">The missense mutations observed in the targeted sequencing cohort include an
independent example of the p.Arg64Cys variant observed in Family 2. Additionally, we
observe an exceedingly rare (ExAC frequency: 4/110,004) and predicted highly deleterious
(CADD score 21.3) variant (p.Asp622His) in two unrelated probands, recruited at distant
sites. Collectively, among familial and individual probands (WES and targeted
sequencing), 13/736 (1.77%) had a <italic>ROBO4</italic> variant that passed <italic>a
priori</italic> filtering constraints while one rare (absent from ExAC) missense
mutation was observed among 376 rigorously phenotyped controls (Two-tailed
Fisher&#x2019;s Exact Test. <italic>P</italic> = 0.0432). Consistent with BAV overall,
the majority of BAV/AscAA probands identified with putative pathogenic
<italic>ROBO4</italic> variants were male (<xref rid="SD1" ref-type="supplementary-material">Supplementary Table 1</xref>); the mechanistic
basis for this observation is unknown.</p>
    <p id="P9">We next sought to elucidate the functional consequence of mutant
<italic>ROBO4</italic> alleles. Histologic and immunofluorescent analyses were
performed on resected ascending aortic aneurysm tissue from patient 1.II:1 and compared
to normal ascending aorta derived from an age- and sex-matched control individual. ROBO4
was strongly expressed in endothelial cells in control aorta as evidenced by
co-localization with platelet endothelial cell adhesion molecule 1 (CD31) but was
diminished in the endothelium in the BAV/AscAA sample (<xref rid="F2" ref-type="fig">Fig. 2a, c</xref>).</p>
    <p id="P10">Both control and diseased aorta showed expression of ROBO4 in the intima in the
absence of co-expression of &#x3B1;-smooth muscle actin (&#x3B1;-SMA), a vascular
smooth muscle cell mesenchymal marker (<xref rid="F2" ref-type="fig">Fig. 2b</xref>).
However, the aneurysm tissue uniquely showed infiltration of ROBO4+ cells into the
aortic media with co-staining for &#x3B1;-SMA. Given ROBO4 expression in the
endothelial lining of the vasculature<sup><xref rid="R22" ref-type="bibr">22</xref></sup> and a described role in establishing endothelial barrier
function<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup>, we hypothesized enhanced vascular permeability
in the ascending aorta of patients with BAV/AscAA. In keeping with this hypothesis,
immunostaining for albumin was restricted to the endothelial surface in control aorta,
but substantial penetration into the aortic intima was observed in patient tissue (<xref rid="F2" ref-type="fig">Fig. 2d</xref>). Histologic analyses showed a strong
fibroproliferative response in the intima and superficial medial layer of patient aorta,
as evidenced by increased cellularity and the accumulation of collagen upon
Masson&#x2019;s trichrome staining. Further, decreased elastin content and fragmentation
and disarray of elastic fibers in the superficial media was revealed upon Verhoeff-Van
Gieson (VVG) staining (<xref rid="F2" ref-type="fig">Fig. 2e</xref>). Collectively,
these data suggest that <italic>ROBO4</italic> mutations disrupt endothelial cellular
performance and barrier function, contributing to pathological remodeling of the aortic
media.</p>
    <p id="P11">To further address the impact of <italic>ROBO4</italic> mutations on endothelial
cell performance, cultured human aortic endothelial cells (HAECs) were transiently
transfected with short interfering RNA (siRNA) against ROBO4 or with constructs
overexpressing either wild-type ROBO4, a form lacking exon 13, or a form with the
p.Arg64Cys missense variant. Further, to assess the individual performance of the ROBO4
variant seen in Family 1, HAECs with silenced endogenous ROBO4 expression (siRNA
targeting sequence in exon 13) were transfected with the expression construct lacking
exon 13 (termed SS-Alone). The expression of wild-type and mutant <italic>ROBO4</italic>
mRNA was assessed by quantitative reverse transcription-PCR (qRT-PCR) (<xref rid="F3" ref-type="fig">Fig. 3a</xref>).</p>
    <p id="P12">Either <italic>ROBO4</italic> silencing or expression of ROBO4 variants resulted
in loss of endothelial barrier function in a dextran permeability assay (<xref rid="F3" ref-type="fig">Fig. 3b</xref>). Loss of barrier function associated with down
regulation of expression of TJP1 and VE-cadherin mRNA and protein, indicative of loss of
tight- and adherens-junction integrity, respectively (<xref rid="F3" ref-type="fig">Fig.
3c</xref>). Other phenotypes seen included induction of expression of &#x3B1;-SMA
and <italic>Snail1</italic> mRNA and cellular elongation and invasion. Assessment of
expression of prototypical target genes suggested a modest decline in bone morphogenetic
protein (BMP) and Notch activity without altered TGF&#x3B2; responses upon ROBO4
silencing. (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig.
3</xref>). Together, these results suggest that reduction or structural disruption
of ROBO4 compromises endothelial identity and performance, as well as its capacity to
suppress transition to a mesenchymal invasive character and synthetic repertoire. These
data suggest that loss-of-function (by functional haploinsufficiency or the antimorphic
effects of overexpressed mutant protein) is the relevant pathogenic mechanism. The
distribution of missense variants along the full length of the gene and protein argues
against particular relevance for any domain-specific function such as homo- or
heterodimerization, interaction with other binding partners or recruitment of SLIT
ligands.</p>
    <p id="P13">ROBO1, ROBO2, SLIT2 and SLIT3 are expressed in or adjacent to the endocardial
cushions and heart valves during mouse development<sup><xref rid="R25" ref-type="bibr">25</xref></sup>. Targeted homozygous disruption of both <italic>Robo1</italic>
and <italic>Robo2</italic> or <italic>Slit3</italic> resulted in highly penetrant septal
defects with variably penetrant valve anomalies, including BAV. We observed that mouse
ROBO4 was expressed in the endocardial layer of the cushions and delamination zones at
embryonic day 11.5 (E11.5; <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 4a</xref>). By E17, ROBO4 was detected in both the endothelial
and interstitial cells of the developing aortic valve and endothelial cells of the
proximal aorta (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 4a,
b</xref>). At 5 weeks after birth, ROBO4 was localized to the endothelial layer of
the ascending aorta and persisted throughout postnatal development (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 4b</xref>). In normal adult
human ascending aorta, ROBO4 is expressed in endothelial and intimal cells (<xref rid="F2" ref-type="fig">Fig. 2</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 4c</xref>). Similarly, robo4 is
known to be expressed in the developing vasculature of zebrafish<sup><xref rid="R26" ref-type="bibr">26</xref></sup>. Together, these results confirm expression of
ROBO4 in cells relevant to the pathogenesis of BAV/AscAA.</p>
    <p id="P14">Next, we established a mutant zebrafish (<italic>Danio rerio</italic>) line
harboring a seven-nucleotide deletion in exon 6 of <italic>robo4</italic>
(<italic>robo4</italic><sup><italic>&#x394;7</italic></sup>; <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 5a</xref>). This frameshift
mutation leads to a low steady-state abundance of <italic>robo4</italic> mRNA due to
nonsense mediated mRNA decay (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 5b</xref>). We observed no gross defect in robo4 mutant larvae
(<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 6</xref>).
Among the adult mutant zebrafish assayed by echocardiography, 7/26 (26.9%)
<italic>robo4</italic><sup><italic>&#x394;7/+</italic></sup> and 4/15 (26.7%)
<italic>robo4</italic><sup><italic>&#x394;7/&#x394;7</italic></sup> zebrafish
displayed regurgitation and/or turbulence across the ventriculo-bulbar valve compared to
4/45 (8.9%) of the wild-type controls (<italic>P</italic> &lt; 0.05; <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 5c-e</xref> and <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 2</xref>). Thus, targeted
disruption of robo4 in zebrafish perturbs outflow tract function. While overt vascular
enlargement was not observed, it is unclear whether the zebrafish system is ideal for
assessment of this specific aspect of the phenotype given substantive anatomic and
physiologic differences from mammals and the limited duration of observation.</p>
    <p id="P15">We next examined the effect of ROBO4 loss of function in mice using the
<italic>Robo4</italic><sup><italic>tm1Lex</italic></sup> model, that lacks exons 1
through 3. <italic>Robo4</italic> transcripts were not detected in homozygous
<italic>Robo4</italic><sup><italic>tm1Lex</italic>/<italic>tm1Lex</italic></sup>
mice via qRT-PCR (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig.
7a</xref>). None of the evaluated heterozygotes
(<italic>Robo4</italic><sup><italic>tm1Lex/+</italic></sup>) presented with any
structural or functional abnormality. Homozygous
<italic>Robo4</italic><sup><italic>tm1Lex</italic>/<italic>tm1Lex</italic></sup>
knockout mice exhibited a complex cardiovascular phenotype that includes a combination
of aortic valve thickening with or without BAV, aortic valve stenosis and/or
regurgitation and/or AscAA. In general, these phenotypes were observed with low
penetrance and male predominance. Overall, at 20 weeks of age, 5/28 (17.9%) male and
2/18 (11.1%) female
<italic>Robo4</italic><sup><italic>tm1Lex</italic>/<italic>tm1Lex</italic></sup>
mice were affected compared to 0/22 (0%) and 0/19 (0%)
<italic>Robo4</italic><sup><italic>+</italic>/<italic>+</italic></sup> males and
females, respectively (<italic>P</italic> &lt; 0.01; <xref rid="F4" ref-type="fig">Fig. 4</xref>). Additionally, one mouse with aortic regurgitation presented with a
quadricuspid aortic valve (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 7b</xref>).</p>
    <p id="P16">We next sought to evaluate the <italic>in vivo</italic> consequence of the
splice mutation (g.124757628C&gt;A, c.2056+1G&gt;T) that we had observed in
Family 1 by establishing a knock-in mouse line harboring a mutation
(<italic>Robo4</italic><sup><italic>Skip13</italic></sup>) at the splice donor site
in intron 13 of <italic>Robo4</italic> (c.2089+1G&gt;T) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 8a</xref>). Sanger sequencing
of cDNA amplicons spanning exons 11&#x2013;14, using mRNA derived from the ascending
aorta of targeted animals, revealed either in-frame skipping of exon 13 (Exons 12/14) or
inclusion of exon 13 with activation of a cryptic splice donor in intron 13 (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 8b, c</xref>). Using
TaqMan&#x2122; probes specific to individual exons or splice junctions, we determined
that wild-type mice show 100% normal splicing (Exons 12/13/14). Representation of Exons
12/13/14, Exons 12/13+Intron 13 and Exons 12/14 transcripts was ~50%, 28% and 22%
or ~0%, 55% and 45% in <italic>Robo4</italic><sup><italic>+/Skip13</italic></sup>
or <italic>Robo4</italic><sup><italic>Skip13/Skip13</italic></sup> animals, respectively
(<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 8d</xref>). We
conclude that the <italic>Robo4</italic><sup><italic>Skip13</italic></sup> mutation
alters pre-mRNA splicing with significant representation of mature mRNA lacking exon
13.</p>
    <p id="P17">Like the knockout mice, <italic>Robo4</italic><sup><italic>Skip13</italic></sup>
mice presented with an incompletely penetrant complex cardiovascular phenotype that
included aortic valve defects and aortic valve dysfunction and AscAA. At 20 weeks, 1/31
(3.2%) <italic>Robo4</italic><sup><italic>Skip13</italic>/<italic>+</italic></sup> and
4/35 (11.4%)
<italic>Robo4</italic><sup><italic>Skip13</italic>/<italic>Skip13</italic></sup>
male mice were affected compared to 0/18
<italic>Robo4</italic><sup><italic>+/+</italic></sup> mice (<italic>P</italic>
&lt; 0.05; <xref rid="F5" ref-type="fig">Fig. 5</xref>).</p>
    <p id="P18">We demonstrate that heterozygous mutations in <italic>ROBO4</italic> are
sufficient to cause a nonsyndromic presentation of BAV/AscAA. The distribution of
expression of ROBO4 in both the developing valve and the ascending aorta is consistent
with the view that BAV and aortic aneurysm present as independent primary manifestations
of the same underlying gene defect, a concept further supported by the presence of
either BAV/AscAA, isolated BAV, or isolated AscAA in family members segregating the same
<italic>ROBO4</italic> mutation. This study highlights many obstacles in the
elucidation of etiologies for BAV/AscAA including a relatively low frequency for
involvement of any specific disease gene (also evident for <italic>NOTCH1</italic> and
<italic>SMAD6</italic>), apparent extreme locus heterogeneity, functional redundancy
within relevant pathways, low penetrance with sex bias, and the lack of signature for
loss-of-function intolerance that is likely related to both the penetrance issue and to
later onset of the phenotype and hence minimal, if any, impact on reproductive fitness.
This study focuses attention on endothelial cell biology in BAV/AscAA, with impairment
of barrier function and/or dysregulation of mesenchymal transition potentially
contributing to disease expression. Prior work has suggested that abnormal plasma
protein (e.g. plasminogen) trafficking in the vessel wall might contribute to aneurysm
phenotypes by enhancing proteolytic activity, TGF&#x3B2; bioavailability or other
mechanisms<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup>. Other studies have suggested an association
between BAV/AscAA and an EnMT-like phenotype in the aortic wall<sup><xref rid="R29" ref-type="bibr">29</xref></sup> and decreased mesenchymal potential of
endothelial cells derived from such patients<sup><xref rid="R30" ref-type="bibr">30</xref></sup>, but neither study had defined the etiology or mechanism for
these findings. While our study of isolated endothelial cells did not reveal a
predominant pathway driving apparent EnMT in the context of ROBO4 deficiency, a
confluence of data provides further incentive to interrogate altered mesenchymal
transition as a pathogenic driver and a therapeutic target in BAV/AscAA using model
systems that mimic the anatomic and physiologic complexity of the left ventricular
outflow tract and ascending aorta.</p>
    <sec id="S1">
      <title>METHODS</title>
      <sec id="S2">
        <title>Study participants.</title>
        <p id="P19">Affected individuals were recruited from the Connective Tissue Clinic at
Johns Hopkins Hospital (H.C.D.), Duke University (G.C.H.), Radboud University
Hospital/Antwerp University Hospital (B.L.L.), Centre Hospitalier Universitaire
Sainte-Justine (G.A.), Karolinska University Hospital (P.E.), University of
Luebeck (S.A.M.), Sickkids Hospital (S.M.), and Erasmus University Medical
Center (M.W.) in strict compliance with all relevant ethical regulations. All
skin biopsies and research protocols were collected in compliance with the
Institutional Review Board at each respective institution after informed consent
was obtained. Echocardiograms were performed and interpreted as previously
described<sup><xref rid="R31" ref-type="bibr">31</xref></sup>.</p>
      </sec>
      <sec id="S3">
        <title>Whole exome sequencing.</title>
        <p id="P20">Genomic DNA was extracted from peripheral blood lymphocytes using
standard protocols. DNA fragmentation was performed using a Covaris S2 system,
and exon capture was performed using the Agilent SureSelect 38 Mb Human All Exon
Target Enrichment system. DNA sequencing was performed on an Illumina Genome
Analyzer IIx instrument with using standard protocols for 75 base pair
paired-end runs.</p>
      </sec>
      <sec id="S4">
        <title>Bioinformatics analysis.</title>
        <p id="P21">Reads were mapped to the human reference genome (UCSC hg19) using the
Burrows-Wheeler Aligner (BWA) and a variant list created using SAMtools, which
were annotated using ANNOVAR<sup><xref rid="R32" ref-type="bibr">32</xref>&#x2013;<xref rid="R34" ref-type="bibr">34</xref></sup>. Local
realignment and recalibration of base call quality scores was performed using
the Genome Analysis Toolkit (GATK)<sup><xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup>. Duplicates
were identified using Picard. We selected for rare variants (dbSNP, exome
variant server, ExAC) and focused only on exonic non-synonymous, splice-site and
insertion and/or deletion (indel) variants. Variants were viewed directly using
the Integrated Genome Viewer (IGV) and excluded if reads were only present in
one direction, if ambiguously mapped reads were present, or if an indel occurred
within 3 base pairs of the end of the read<sup><xref rid="R37" ref-type="bibr">37</xref></sup>.</p>
      </sec>
      <sec id="S5">
        <title>Mutation validation and Sanger Sequencing of candidate genes.</title>
        <p id="P22">Bidirectional Sanger DNA sequencing assays were performed using primers
designed 60&#x2013;120 base pairs from the variants or intron-exon boundaries to
confirm candidate variants or sequence candidate genes. PCR was performed using
a DNA Engine Dyad thermal cycler (Bio-Rad). Phusion Flash High Fidelity PCR
Master Mix was used in accordance with the manufacturer&#x2019;s instructions
for each primer set (Thermo Scientific). Cycle sequencing was performed using
the BigDye Terminator v3.1 kit and an ABI 3730xl DNA Analyzer in accordance with
the manufacturer&#x2019;s instructions (Life Technologies). Samples were
purified using the QIAquick PCR Purification kit (Qiagen).</p>
      </sec>
      <sec id="S6">
        <title>Targeted sequencing.</title>
        <p id="P23">Enrichment for all exons of <italic>ROBO4</italic>, including &#xB1;10
nucleotides of adjacent intronic sequences, was performed with a custom Haloplex
target enrichment kit per instructions of the manufacturer (Agilent
Technologies, USA). Probe design covered a theoretical 99.7% of the complete
target region. Pooled samples were sequenced either on a HiSeq 2500 (Illumina,
USA) with 2&#xD7;150 base pair reads or on a HiSeq 1500 (Illumina, USA) with
2&#xD7;100 base pair reads.</p>
      </sec>
      <sec id="S7">
        <title>Cell culture and transfection.</title>
        <p id="P24">Primary human dermal fibroblasts were derived from forearm skin biopsies
from one control individual, a control cell line (ATCC), or a single proband.
Cells were cultured in DMEM supplemented with 10% FBS in the presence of
antibiotics and were passaged at confluence. Human aortic endothelial cells
(HAEC) (Promocell, Heidelberg) were cultured in EGM2 BulletKi (Lonza,
CC-3156/CC-4176) and used for experiments at P2-P4. For initial transfection
experiments, cells were seeded at 60&#x2013;70% confluence.
<italic>ROBO4</italic> constructs were mixed with Lipofectamine 3000
(Invitrogen), diluted in EGM2 (without antibiotics) (for constructs, see <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>),
and treated for 24 hours. HAEC media was then replaced and allowed to culture
for an additional 48 hours. Transfection efficiency was measured via qRT-PCR and
immunofluorescence.</p>
      </sec>
      <sec id="S8">
        <title>RNA isolation and qRT-PCR.</title>
        <p id="P25">For human and mice samples, RNA extractions were performed using a
Qiagen total RNA purification kit (Qiagen) and RNA was reverse transcribed to
cDNA using the SuperScript III RT-PCR kit with oligo(dT) primer (Invitrogen).
Real-time PCR experiments were conducted using the FAM-MGB PCR system (Applied
Biosystems) on QuantStudio 7 Real-Time ABI 384 cycler, with 40 cycles per
sample. Primers were normalized to 18S or GAPDH. The following pre-validated
probes were used for mRNA analysis: H200219408_m1 (<italic>Robo4</italic>),
Hs01551861_m1 (<italic>TJP1</italic>), Hs00901463_m1 (<italic>CDH5</italic>),
Hs00426835_g1 (<italic>ACTA2</italic>), Hs00195591_m1 (<italic>SNAI1</italic>),
Hs00170014_m1 (<italic>CTGF</italic>), Hs00167155_m1
(<italic>SERPINE1),</italic> Hs03676575_s1 (<italic>Id1</italic>),
Hs04187239_m1 (Id2), Hs00954037_g1 (Id3), Hs01114113_m1 (<italic>Hey1),</italic>
Hs00232622_m1 (<italic>Hey2),</italic> Hs03003631_g1 (18S), and Hs02758991_g1
(<italic>GAPDH</italic>) (Life technologies). For zebrafish, RNA extracts
were prepared from isolated wild-type or <italic>robo4</italic> knockout adult
hearts using RNA TRIzol (Ambion) and cDNA was synthesized using SuperScript III
Reverse Transcriptase kit (ThermoFisher Scientific). Two sets of specific
primers spanning the junctions of exons 9 and 10 and of exons 16 and 17 were
designed (see <xref rid="SD1" ref-type="supplementary-material">Supplementary
Table 5</xref>). All qRT-PCR data was obtained using the ViiA 7 Real-Time
PCR System (Applied Biosystems) and SYBR Green PCR Mix (ThermoFisher).</p>
      </sec>
      <sec id="S9">
        <title>Antibody staining.</title>
        <p id="P26">Samples were fixed in 4% paraformaldehyde overnight at 4&#xB0;C.
Samples were then washed for 15 minutes on a rocker 3 times with PBS,
permeabilized with 0.2% Triton-X 100 (VWR International, Radnor, PA) for 10
minutes, and washed another 3 times with PBS. Samples were incubated overnight
at 4&#xB0;C in a 1% BSA (Rockland Immunochemicals) blocking solution followed
by another 4&#xB0;C overnight incubation with ROBO4 (Abcam, ab103674), ROBO4
(Santa Cruz, sc-46497), CD31 (Biocare Medical, CM303A), PECAM1 (Santa Cruz,
sc-1506), CDH5 (Santa Cruz, sc-28644), TJP1 (Santa Cruz, sc-8146), ACTA2 (Abcam,
ab7817), or ALB (Santa Cruz, sc-46293). After 3 washes for 15 minutes with PBS,
samples were exposed to Alexa Fluor 488 or 568 conjugated (Invitrogen),
species-specific secondary antibodies at 1:100 in 1% BSA for 2 hours at room
temperature. Three more washes with PBS for 15 minutes were followed by
incubation with either DRAQ5 (far-red) nuclear stain or DAPI (UV) nuclear stain
(Enzo Life Sciences) at 1:1000.</p>
      </sec>
      <sec id="S10">
        <title>Permeability assay.</title>
        <p id="P27">Permeability assays were performed as described previously<sup><xref rid="R38" ref-type="bibr">38</xref></sup>. HAECs were utilized at or
before passage six. Cells were detached using 0.05% trypsin-EDTA, pelleted, then
re-suspended in a growth medium to a concentration of 0.5&#x2013;1X at
10<sup>6</sup> cells/mL. Dry collagen pre-coated porous inserts were
rehydrated for 15 minutes in a growth medium prior to cell seeding (1.0um pores,
EMD Millipore). HAECs were seeded in 200 &#x3BC;L of growth medium per 24 well
insert. 500 &#x3BC;L were added to each receiver plate well. HAECs were
cultured in a 37&#xB0;C/5% CO<sub>2</sub> tissue culture incubator for 72
hours to allow for a monolayer formation. Following endothelial monolayer
formation, growth medium was carefully removed. This was replaced with medium
containing different <italic>ROBO4</italic> constructs (see <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>). Samples
were returned to 37&#xB0;C incubation for 24 hours. Afterwards, the treatment
medium was carefully removed. A high molecular weight FITC-dextran solution
(40kDA) was created by 1:40 dilution in a growth medium and added at 150
&#x3BC;L. Growth medium was added to each receiver plate well at 500 &#x3BC;L
(24-well). The FITC-dextran permeated the monolayers for 2 hours. The inserts
were removed from the receiver wells to stop permeation. The medium in the
receiver wells was then thoroughly mixed and 100 &#x3BC;L was removed from each
well to a black 96-well opaque plate for fluorescence measurement. Permeability
was quantified on a Synergy-II fluorescent plate reader (Biotek) via
fluorescence at 485nm excitation/535nm emission wavelengths (1 second
fluorescent count time). The endothelial monolayer was stained after completion
of FITC-dextran permeability testing for subsequent confocal imaging.</p>
      </sec>
      <sec id="S11">
        <title>Cell morphology assay.</title>
        <p id="P28">Cell shape was calculated as previously described<sup><xref rid="R39" ref-type="bibr">39</xref></sup> using ImageJ (<ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/plugins/circularity.html">https://imagej.nih.gov/ij/plugins/circularity.html</ext-link>). Cell shape
changes were automatically tracked over subsequent images, and quantified as a
cell circularity index (CI&#x200A;=&#x200A;4*Pi*(Area/Perimeter2)). A
circularity value of 1.0 indicates a perfect circle. As the value approaches
0.0, it indicates an increasingly elongated polygon.</p>
      </sec>
      <sec id="S12">
        <title>Endothelial aggregate invasion assay.</title>
        <p id="P29">For invasion assays, cells were re-suspended in culture media and
allowed to aggregate overnight in hanging drop culture (20&#x2009;&#x3BC;L;
20,000&#x2009;cells). The aggregates were then placed on the surface of
neutralized type I collagen hydrogels (1.5&#x2009;mg/mL) as previously
described<sup><xref rid="R40" ref-type="bibr">40</xref></sup> and
allowed to adhere for 2&#x2009;hours before adding treatments. Cultures were
then transfected for 24 hours with the <italic>ROBO4</italic> constructs (see
<xref rid="SD1" ref-type="supplementary-material">Supplementary Table
5</xref>) and maintained for another 72 hours. Cell invasion was quantified
manually at a 50-&#x3BC;m depth into the gel and normalized to control.</p>
      </sec>
      <sec id="S13">
        <title>Proliferation assay.</title>
        <p id="P30">5-bromo-2&#x2032;-deoxyuridine (BrdU) incorporation was used to detect
proliferating cells as described previously<sup><xref rid="R41" ref-type="bibr">41</xref></sup>. Cultures were transfected for 24 hours with the
<italic>ROBO4</italic> constructs (see <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 5</xref>). BrdU
labeling reagent (Invitrogen) was added to the culture media for 12 hours after
treatment. After 24 hours, cells were fixed and targeted with a monoclonal
Anti-BrdU Alexa Fluor 488 conjugate (PRB-1, Invitrogen) while total DNA was
counterstained using a DAPI dye. Positive fluorescent areas for each cell were
measured using ImageJ and normalized by cell nuclei.</p>
      </sec>
      <sec id="S14">
        <title>Scratch assay.</title>
        <p id="P31">Migratory ability was tested as described previously<sup><xref rid="R42" ref-type="bibr">42</xref></sup>. Briefly, cells were cultured to
confluency and then transfected for 24 hours with the <italic>ROBO4</italic>
constructs. A scratch was then introduced using a 200-&#x3BC;l pipette tip. The
cells were then incubated at 37&#xB0;C and observed at 24 hours. Differences
in filling in the scratch were observed to establish the capability of cellular
migration.</p>
      </sec>
      <sec id="S15">
        <title>Zebrafish and mouse maintenance.</title>
        <p id="P32">Adult AB and <italic>robo4</italic><sup><italic>&#x394;7</italic></sup>
mutant zebrafish lines were maintained in system water according to standard
methods<sup><xref rid="R43" ref-type="bibr">43</xref></sup>. Mice were
housed in the Johns Hopkins University School of Medicine East Baltimore campus.
All strains were maintained on a mixed C57BL/6J and F129/SVE background. All
zebrafish and mice upkeep and experimental procedures were in accordance with
the ethical permits set by the Johns Hopkins Institutional Animal Care and Use
Committee.</p>
      </sec>
      <sec id="S16">
        <title>Generation of a <italic>robo4</italic> knockout zebrafish line by
CRISPR/Cas9.</title>
        <p id="P33">We designed a single guide RNA (gRNA, see sequences in <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 6</xref>) to target
the <italic>robo4</italic> gene (gRNA<sup><italic>robo4</italic></sup>), using
ZiFit<sup><xref rid="R44" ref-type="bibr">44</xref>,<xref rid="R45" ref-type="bibr">45</xref></sup>. Cas9 RNA was synthesized from
linearized pCS2-nls-zCas9-nls (AddGene, no. 47929)<sup><xref rid="R46" ref-type="bibr">46</xref></sup>. We injected 100 ng/nL of gRNA and 300
ng of Cas9 in a 5-&#x3BC;L solution into 1-cell wild-type (AB) zebrafish
embryos and raised them to maturity (F<sub>0</sub>). To identify fish capable of
germline transmission, we crossed F<sub>0</sub> males with AB females. Germline
transmission was confirmed by Surveyor Assay (IDT) in pooled F<sub>1</sub>
embryos (<italic>n</italic> = 50) followed by Sanger sequencing. Heterozygous
F<sub>1</sub> adults with the same seven base pair deletion were inbred to
establish the line (<italic>robo4</italic><sup><italic>jh176</italic></sup>).
All subsequent generations were genotyped using primer set F2 and R2 (see <xref rid="SD1" ref-type="supplementary-material">Supplementary Table
6</xref>).</p>
      </sec>
      <sec id="S17">
        <title><italic>Robo4</italic> knockout mice and generation of <italic>Robo4</italic>
knock-in mice.</title>
        <p id="P34"><italic>Robo4</italic><sup><italic>tm1Lex</italic></sup> knockout mice
were purchased through the mutant mouse resource and research centers supported
by the NIH (MGI:5007309, Lexicon Pharmaceuticals). The mice were bred in a
heterozygous state on a mixed background of 129S5/SvEvBrd and C57BL6/J. To
generate <italic>Robo4</italic> knock-in mice, we targeted the
<italic>Robo4</italic> locus using CRISPR/Cas9. Two single-guide RNA (sgRNA)
sequences (see <xref rid="SD1" ref-type="supplementary-material">Supplementary
Table 7</xref>) were designed to target exon 13 of <italic>Robo4</italic>
(NC_000074.5) using a gRNA CRISPR design tool (<ext-link ext-link-type="uri" xlink:href="http://crispr.technology/)47">http://crispr.technology/)<sup><xref rid="R47" ref-type="bibr">47</xref></sup></ext-link>. Neither gRNA was predicted to have any
off-target effects. These oligonucleotides were cloned into a pX459
plasmid<sup><xref rid="R48" ref-type="bibr">48</xref></sup> (Addgene,
no. 48139) and appended with a T7 promoter. The sgRNA was transcribed in vitro.
The homology directed repair (HDR) template was purchased as a 4nm Ultramer
(IDT, see <xref rid="SD1" ref-type="supplementary-material">Supplementary Table
6</xref>). The sgRNA, Cas9 (TriLink BioTechnologies), and HDR were
co-injected into C57BL/6J zygotes (Johns Hopkins University Transgenic Core).
Pups (<italic>n</italic> = 41) were screened for locus editing by Sanger
sequencing (IDT, see <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 7</xref>). Mice
(<italic>Robo4</italic><sup><italic>Skip13</italic></sup>) were
subsequently genotyped by Sanger sequencing (271 base pair amplicon). Mice were
then crossed to a mixed background (129S5/SvEvBrd and C57BL6).</p>
      </sec>
      <sec id="S18">
        <title>Zebrafish and mice echocardiography.</title>
        <p id="P35">For zebrafish, we used the Vevo 2100 Imaging System equipped with a 70
MHz ultrasound transducer (VisualSonics&#xAE;, Toronto, ON, Canada). The
zebrafish were anesthetized by placing the fish into a plastic cup filled with
100 ml of 168 &#x3BC;g/ml MS-222 (Tricaine methanesulfonate, Fluka Analytical).
For mice, echocardiograms were undertaken on awake, unsedated mice using the
Vevo 2100 Imaging System (VisualSonics&#xAE;, Toronto, ON, Canada) and a 40
MHz transducer. Echocardiographic recordings for the mice were taken using a
parasternal long-axis or sagittal short axis view; 3 independent measurements of
the maximal internal dimension at the sinus of Valsalva and ascending aorta were
made and averaged. All data acquisition and measurements for mice and zebrafish
were performed blinded to the genotype.</p>
      </sec>
      <sec id="S19">
        <title>Statistics and reproducibility</title>
        <p id="P36">For experiments including multiple comparisons, <italic>P</italic>
values refer to one-way ANOVA followed by Tukey&#x2019;s post-hoc test. For
experiments including only one comparison, <italic>P</italic> values refer to
unpaired two-tailed Student&#x2019;s <italic>t</italic>-test, two-tailed
Welch&#x2019;s <italic>t</italic>-test, or two- or one-tailed Fisher&#x2019;s
exact test. <italic>P</italic> values less than 0.05 were considered
significant. <italic>P</italic> values are provided as exact figures where
possible, otherwise reported as a range when a large amount of comparisons were
performed in a single figure or panel. Data are shown as mean &#xB1; standard
error (SE) or standard deviation (SD). Further information on experimental
design and reagents can be seen in the Life Sciences Reporting Summary</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="SM1">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHMS1508198-supplement-1.pdf" orientation="portrait" xlink:type="simple" id="d36e1439" position="anchor"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="SD2">
        <label>2</label>
        <media xlink:href="NIHMS1508198-supplement-2.doc" orientation="portrait" xlink:type="simple" id="d36e1443" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S20">
      <title>ACKNOWLEDGEMENTS</title>
      <p id="P37">The authors gratefully acknowledge support from the Leducq Foundation to
A.S.M. and H.C.D., from NHGRI (1U54HG006542) to D.V. and J.L., from NHLBI (HL110328,
HL128745) and NIH (S10OD012287) to J.T.B. We also thank the American Philosophical
Society for support of H.A. through the Daland Fellowship. Additionally, we thank
Johns Hopkins University School of Medicine, McKusick Nathans Institute of Genetic
Medicine Center for Functional Investigation in Zebrafish (FINZ) for their technical
support and to Corinne Boehm for her assistance in depositing variant information to
ClinVar. B.L.L. is senior clinical investigator of the Fund for Scientific Research,
Flanders and holds a starting grant from the European Research Council
(ERC-StG-2012&#x2013;30972-BRAVE). A.V. is a postdoc researcher supported by the
Fund for Scientific Research Flanders. I.L. is supported by a PhD grant from the
Agency for Innovation by Science and Technology (IWT). M.E.L. is supported by the
Toomey Fund for Aortic Dissection Research and the Fredman Fellowship in Aortic
Disease. G.A. is a FQRS Senior Clinical Research Fellow.</p>
    </ack>
    <fn-group>
      <fn fn-type="COI-statement" id="FN2">
        <p id="P38">COMPETING FINANCIAL INTERESTS</p>
        <p id="P39">The authors declare no competing financial interests.</p>
      </fn>
      <fn id="FN3">
        <p id="P40">DATA AVAILABILITY</p>
        <p id="P41">ROBO4 variants were submitted to ClinVar (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>) and have the following
accession codes: SCV000804228, SCV000804229, SCV000804230, SCV000804231,
SCV000804232, SCV000804233, SCV000804234, SCV000804235, SCV000804236,
SCV000804237, SCV000804238, SCV000804239. Exome sequencing data is not publicly
available due to consent restrictions.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><name><surname>Fedak</surname><given-names>PWM</given-names></name>
<etal/>
<article-title>Clinical and pathophysiological implications of a bicuspid aortic
valve</article-title>. <source>Circulation</source>
<volume>106</volume>, <fpage>900</fpage>&#x2013;<lpage>904</lpage>
(<year>2002</year>).<pub-id pub-id-type="pmid">12186790</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><name><surname>Mack</surname><given-names>G</given-names></name> &amp; <name><surname>Silberbach</surname><given-names>M</given-names></name>
<article-title>Aortic and pulmonary stenosis</article-title>. <source>Pediatr.
Rev</source>
<volume>21</volume>, <fpage>79</fpage>&#x2013;<lpage>85</lpage>
(<year>2000</year>).<pub-id pub-id-type="pmid">10702320</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><name><surname>Ward</surname><given-names>C</given-names></name>
<article-title>Clinical significance of the bicuspid aortic
valve</article-title>. <source>Heart</source>
<volume>83</volume>, <fpage>81</fpage>&#x2013;<lpage>85</lpage>
(<year>2000</year>).<pub-id pub-id-type="pmid">10618341</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><name><surname>Tadros</surname><given-names>TM</given-names></name>, <name><surname>Klein</surname><given-names>MD</given-names></name> &amp; <name><surname>Shapira</surname><given-names>OM</given-names></name>
<article-title>Ascending aortic dilatation associated with bicuspid aortic
valve. Pathophysiology, molecular biology, and clinical
implications</article-title>. <source>Circulation</source>
(<year>2009</year>). doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.795401</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><name><surname>Cripe</surname><given-names>L</given-names></name>, <name><surname>Andelfinger</surname><given-names>G</given-names></name>, <name><surname>Martin</surname><given-names>LJ</given-names></name>, <name><surname>Shooner</surname><given-names>K</given-names></name> &amp; <name><surname>Benson</surname><given-names>DW</given-names></name>
<article-title>Bicuspid aortic valve is heritable</article-title>. <source>J.
Am. Coll. Cardiol</source>
<volume>44</volume>, <fpage>138</fpage>&#x2013;<lpage>143</lpage>
(<year>2004</year>).<pub-id pub-id-type="pmid">15234422</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><name><surname>Garg</surname><given-names>V</given-names></name>
<etal/>
<article-title>Mutations in NOTCH1 cause aortic valve disease</article-title>.
<source>Nature</source>
<volume>437</volume>, <fpage>270</fpage>&#x2013;<lpage>274</lpage>
(<year>2005</year>).<pub-id pub-id-type="pmid">16025100</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><name><surname>McKellar</surname><given-names>SH</given-names></name>
<etal/>
<article-title>Novel NOTCH1 mutations in patients with bicuspid aortic valve
disease and thoracic aortic aneurysms</article-title>. <source>J. Thorac.
Cardiovasc. Surg</source>
<volume>134</volume>, <fpage>290</fpage>&#x2013;<lpage>6</lpage>
(<year>2007</year>).<pub-id pub-id-type="pmid">17662764</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>HL</given-names></name>
<etal/>
<article-title>Nonsynonymous variants in the SMAD6 gene predispose to congenital
cardiovascular malformation</article-title>. <source>Hum. Mutat</source>
<volume>33</volume>, <fpage>720</fpage>&#x2013;<lpage>727</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22275001</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><name><surname>Clementi</surname><given-names>M</given-names></name>, <name><surname>Notari</surname><given-names>L</given-names></name>, <name><surname>Borghi</surname><given-names>A</given-names></name> &amp; <name><surname>Tenconi</surname><given-names>R</given-names></name>
<article-title>Familial congenital bicuspid aortic valve: A disorder of
uncertain inheritance</article-title>. <source>Am. J. Med. Genet</source>
<volume>62</volume>, <fpage>336</fpage>&#x2013;<lpage>338</lpage>
(<year>1996</year>).<pub-id pub-id-type="pmid">8723060</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><name><surname>Huntington</surname><given-names>K</given-names></name>, <name><surname>Hunter</surname><given-names>AGW</given-names></name> &amp; <name><surname>Chan</surname><given-names>KL</given-names></name>
<article-title>A prospective study to assess the frequency of familial
clustering of congenital bicuspid aortic valve</article-title>. <source>J.
Am. Coll. Cardiol</source>
<volume>30</volume>, <fpage>1809</fpage>&#x2013;<lpage>1812</lpage>
(<year>1997</year>).<pub-id pub-id-type="pmid">9385911</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><name><surname>Mckusick</surname><given-names>VA</given-names></name>, <name><surname>Logue</surname><given-names>RB</given-names></name> &amp; <name><surname>Bahnson</surname><given-names>HT</given-names></name>
<article-title>Association of Aortic Valvular Disease and Cystic Medial Necrosis
of the Ascending Aorta</article-title>. <source>Circulation</source>
<volume>16</volume>, <fpage>188</fpage>&#x2013;<lpage>194</lpage>
(<year>1957</year>).<pub-id pub-id-type="pmid">13447162</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><name><surname>Loscalzo</surname><given-names>ML</given-names></name>
<etal/>
<article-title>Familial thoracic aortic dilation and bicommissural aortic valve:
A prospective analysis of natural history and inheritance</article-title>.
<source>Am. J. Med. Genet. Part A</source>
<volume>143</volume>, <fpage>1960</fpage>&#x2013;<lpage>1967</lpage>
(<year>2007</year>).</mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><name><surname>Isselbacher</surname><given-names>EM</given-names></name>
<article-title>Thoracic and abdominal aortic aneurysms</article-title>.
<source>Circulation</source>
<volume>111</volume>, <fpage>816</fpage>&#x2013;<lpage>828</lpage>
(<year>2005</year>).<pub-id pub-id-type="pmid">15710776</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><name><surname>Williams</surname><given-names>JA</given-names></name>
<etal/>
<article-title>Early Surgical Experience With Loeys-Dietz: A New Syndrome of
Aggressive Thoracic Aortic Aneurysm Disease</article-title>. <source>Ann.
Thorac. Surg</source>
<volume>83</volume>, (<year>2007</year>).</mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><name><surname>Van Hemelrijk</surname><given-names>C</given-names></name>, <name><surname>Renard</surname><given-names>M</given-names></name> &amp; <name><surname>Loeys</surname><given-names>B</given-names></name>
<article-title>The Loeys-Dietz syndrome: an update for the
clinician</article-title>. <source>Curr. Opin. Cardiol</source>
<volume>25</volume>, <fpage>546</fpage>&#x2013;<lpage>551</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20838339</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>D-C</given-names></name>
<etal/>
<article-title>Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic
aortic aneurysms and dissections</article-title>. <source>Nat.
Genet</source>
<volume>39</volume>, <fpage>1488</fpage>&#x2013;<lpage>1493</lpage>
(<year>2007</year>).<pub-id pub-id-type="pmid">17994018</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17.</label>
        <mixed-citation publication-type="journal"><name><surname>Pereira</surname><given-names>L</given-names></name>
<etal/>
<article-title>Targetting of the gene encoding fibrillin-1 recapitulates the
vascular aspect of Marfan syndrome</article-title>. <source>Nat
Genet</source>
<volume>17</volume>, <fpage>218</fpage>&#x2013;<lpage>222</lpage>
(<year>1997</year>).<pub-id pub-id-type="pmid">9326947</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18.</label>
        <mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>L</given-names></name>
<etal/>
<article-title>Mutations in myosin heavy chain 11 cause a syndrome associating
thoracic aortic aneurysm/aortic dissection and patent ductus
arteriosus</article-title>. <source>Nat. Genet</source>
<volume>38</volume>, <fpage>343</fpage>&#x2013;<lpage>349</lpage>
(<year>2006</year>).<pub-id pub-id-type="pmid">16444274</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19.</label>
        <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>L</given-names></name>
<etal/>
<article-title>Mutations in myosin light chain kinase cause familial aortic
dissections</article-title>. <source>Am. J. Hum. Genet</source>
<volume>87</volume>, <fpage>701</fpage>&#x2013;<lpage>707</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">21055718</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20.</label>
        <mixed-citation publication-type="journal"><name><surname>van de Laar</surname><given-names>IMBH</given-names></name>
<etal/>
<article-title>Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis
syndrome</article-title>. <source>J. Med. Genet</source>
<volume>49</volume>, <fpage>47</fpage>&#x2013;<lpage>57</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22167769</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21.</label>
        <mixed-citation publication-type="journal"><name><surname>Loeys</surname><given-names>BL</given-names></name>
<etal/>
<article-title>Aneurysm syndromes caused by mutations in the TGF-beta
receptor</article-title>. <source>N. Engl. J. Med</source>
<volume>355</volume>, <fpage>788</fpage>&#x2013;<lpage>798</lpage>
(<year>2006</year>).<pub-id pub-id-type="pmid">16928994</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22.</label>
        <mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>KW</given-names></name>
<etal/>
<article-title>Robo4 is a vascular-specific receptor that inhibits endothelial
migration</article-title>. <source>Dev. Biol</source>
<volume>261</volume>, <fpage>251</fpage>&#x2013;<lpage>267</lpage>
(<year>2003</year>).<pub-id pub-id-type="pmid">12941633</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23.</label>
        <mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>C. a</given-names></name>
<etal/>
<article-title>Robo4 stabilizes the vascular network by inhibiting pathologic
angiogenesis and endothelial hyperpermeability</article-title>. <source>Nat.
Med</source>
<volume>14</volume>, <fpage>448</fpage>&#x2013;<lpage>453</lpage>
(<year>2008</year>).<pub-id pub-id-type="pmid">18345009</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24.</label>
        <mixed-citation publication-type="journal"><name><surname>Cai</surname><given-names>H</given-names></name>
<etal/>
<article-title>Roundabout 4 Regulates Blood-Tumor Barrier Permeability Through
the Modulation of ZO-1, Occludin, and Claudin-5 Expression</article-title>.
<source>J. Neuropathol. Exp. Neurol</source>
<volume>74</volume>, <fpage>25</fpage>&#x2013;<lpage>37</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">25470344</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25.</label>
        <mixed-citation publication-type="journal"><name><surname>Mommersteeg</surname><given-names>MTM</given-names></name>, <name><surname>Yeh</surname><given-names>ML</given-names></name>, <name><surname>Parnavelas</surname><given-names>JG</given-names></name> &amp; <name><surname>Andrews</surname><given-names>WD</given-names></name>
<article-title>Disrupted Slit-Robo signalling results in membranous ventricular
septum defects and bicuspid aortic valves</article-title>.
<source>Cardiovasc. Res</source>
<volume>106</volume>, <fpage>55</fpage>&#x2013;<lpage>66</lpage>
(<year>2015</year>).<pub-id pub-id-type="pmid">25691540</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26.</label>
        <mixed-citation publication-type="journal"><name><surname>Bedell</surname><given-names>VM</given-names></name>
<etal/>
<article-title>Roundabout4 Is Essential for Angiogenesis in
Vivo</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A</source>
<volume>102</volume>, <fpage>6373</fpage>&#x2013;<lpage>8</lpage>
(<year>2005</year>).<pub-id pub-id-type="pmid">15849270</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>27.</label>
        <mixed-citation publication-type="journal"><name><surname>Carmeliet</surname><given-names>P</given-names></name>
<etal/>
<article-title>Urokinase-generated plasmin activates matrix metalloproteinases
during aneurysm formation</article-title>. <source>Nat Genet</source>.
<volume>17</volume>(<issue>4</issue>),
<fpage>439</fpage>&#x2013;<lpage>444</lpage>
(<year>1997</year>).<pub-id pub-id-type="pmid">9398846</pub-id></mixed-citation>
      </ref>
      <ref id="R28">
        <label>28.</label>
        <mixed-citation publication-type="journal"><name><surname>Borges</surname><given-names>LF</given-names></name>. <etal/>
<article-title>Fibrinolytic activity is associated with presence of cystic
medial degeneration in aneurysms of the ascending aorta</article-title>.
<source>Histopathology</source>
<volume>57</volume>(<issue>6</issue>),
<fpage>917</fpage>&#x2013;<lpage>932</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">21166705</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29.</label>
        <mixed-citation publication-type="journal"><name><surname>Maleki</surname><given-names>S</given-names></name>
<etal/>
<article-title>Mesenchymal state of intimal cells may explain higher propensity
to ascending aortic aneurysm in bicuspid aortic valves</article-title>.
<source>Sci. Rep</source>. <volume>6</volume>, <fpage>35712</fpage>
(<year>2016</year>).<pub-id pub-id-type="pmid">27779199</pub-id></mixed-citation>
      </ref>
      <ref id="R30">
        <label>30.</label>
        <mixed-citation publication-type="journal"><name><surname>Kostina</surname><given-names>AS</given-names></name>
<etal/>
<article-title>Notch-dependent EMT is attenuated in patients with aortic
aneurysm and bicuspid aortic valve</article-title>. <source>Biochim.
Biophys. Acta - Mol. Basis Dis</source>
<volume>1862</volume>, <fpage>733</fpage>&#x2013;<lpage>740</lpage>
(<year>2016</year>).</mixed-citation>
      </ref>
      <ref id="R31">
        <label>31.</label>
        <mixed-citation publication-type="journal"><name><surname>Brooke</surname><given-names>BS</given-names></name>
<etal/>
<article-title>Angiotensin II blockade and aortic-root dilation in
Marfan&#x2019;s syndrome</article-title>. <source>N. Engl. J. Med</source>
<volume>358</volume>, <fpage>2787</fpage>&#x2013;<lpage>95</lpage>
(<year>2008</year>).<pub-id pub-id-type="pmid">18579813</pub-id></mixed-citation>
      </ref>
      <ref id="R32">
        <label>32.</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name> &amp; <name><surname>Durbin</surname><given-names>R</given-names></name>
<article-title>Fast and accurate short read alignment with Burrows-Wheeler
transform</article-title>. <source>Bioinformatics</source>
<volume>25</volume>, <fpage>1754</fpage>&#x2013;<lpage>1760</lpage>
(<year>2009</year>).<pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
      </ref>
      <ref id="R33">
        <label>33.</label>
        <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>
<etal/>
<article-title>The Sequence Alignment / Map format and SAMtools</article-title>.
<source>Bioinformatics</source>
<volume>25</volume>, <fpage>2078</fpage>&#x2013;<lpage>2079</lpage>
(<year>2009</year>).<pub-id pub-id-type="pmid">19505943</pub-id></mixed-citation>
      </ref>
      <ref id="R34">
        <label>34.</label>
        <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name> &amp; <name><surname>Hakonarson</surname><given-names>H</given-names></name>
<article-title>ANNOVAR: functional annotation of genetic variants from
high-throughput sequencing data</article-title>. <source>Nucleic Acids
Res</source>. <volume>38</volume>, <fpage>e164</fpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20601685</pub-id></mixed-citation>
      </ref>
      <ref id="R35">
        <label>35.</label>
        <mixed-citation publication-type="journal"><name><surname>McKenna</surname><given-names>A</given-names></name>
<etal/>
<article-title>The genome analysis toolkit: A MapReduce framework for analyzing
next-generation DNA sequencing data</article-title>. <source>Genome
Res</source>. <volume>20</volume>,
<fpage>1297</fpage>&#x2013;<lpage>1303</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20644199</pub-id></mixed-citation>
      </ref>
      <ref id="R36">
        <label>36.</label>
        <mixed-citation publication-type="journal"><name><surname>DePristo</surname><given-names>M. a.</given-names></name>
<etal/>
<article-title>A framework for variation discovery and genotyping using next-
generation DNA sequencing data</article-title>. <source>Nat Genet</source>
<volume>43</volume>, <fpage>491</fpage>&#x2013;<lpage>498</lpage>
(<year>2011</year>).<pub-id pub-id-type="pmid">21478889</pub-id></mixed-citation>
      </ref>
      <ref id="R37">
        <label>37.</label>
        <mixed-citation publication-type="journal"><name><surname>Robinson</surname><given-names>JT</given-names></name>
<etal/>
<article-title>Integrative genomics viewer</article-title>. <source>Nat.
Biotechnol</source>. <volume>29</volume>,
<fpage>24</fpage>&#x2013;<lpage>26</lpage>
(<year>2011</year>).<pub-id pub-id-type="pmid">21221095</pub-id></mixed-citation>
      </ref>
      <ref id="R38">
        <label>38.</label>
        <mixed-citation publication-type="other"><name><surname>Anderl</surname><given-names>J</given-names></name>, <name><surname>Ma</surname><given-names>J</given-names></name> &amp; <name><surname>Armstrong</surname><given-names>L</given-names></name>
<source>Improved Assays for Quantification of In Vitro Vascular
Permeability</source>. <fpage>10</fpage>&#x2013;<lpage>14</lpage>
doi:<pub-id pub-id-type="doi">10.1038/an8623</pub-id></mixed-citation>
      </ref>
      <ref id="R39">
        <label>39.</label>
        <mixed-citation publication-type="journal"><name><surname>Gould</surname><given-names>RA</given-names></name>
<etal/>
<article-title>Multi-Scale Biomechanical Remodeling in Aging and Genetic Mutant
Murine Mitral Valve Leaflets: Insights into Marfan Syndrome</article-title>.
<source>PLoS One</source>
<volume>7</volume>, (<year>2012</year>).</mixed-citation>
      </ref>
      <ref id="R40">
        <label>40.</label>
        <mixed-citation publication-type="journal"><name><surname>Chiu</surname><given-names>Y-N</given-names></name>, <name><surname>Norris</surname><given-names>R. a</given-names></name>, <name><surname>Mahler</surname><given-names>G</given-names></name>, <name><surname>Recknagel</surname><given-names>A</given-names></name> &amp; <name><surname>Butcher</surname><given-names>JT</given-names></name>. <article-title>Transforming growth factor &#x3B2;, bone morphogenetic
protein, and vascular endothelial growth factor mediate phenotype maturation
and tissue remodeling by embryonic valve progenitor cells: relevance for
heart valve tissue engineering</article-title>. <source>Tissue Eng. Part
A</source>
<volume>16</volume>, <fpage>3375</fpage>&#x2013;<lpage>3383</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20629541</pub-id></mixed-citation>
      </ref>
      <ref id="R41">
        <label>41.</label>
        <mixed-citation publication-type="journal"><name><surname>Gould</surname><given-names>RA</given-names></name>
<etal/>
<article-title>Cyclic strain anisotropy regulates valvular interstitial cell
phenotype and tissue remodeling in three-dimensional
culture</article-title>. <source>Acta Biomater</source>. <volume>8</volume>,
<fpage>1710</fpage>&#x2013;<lpage>1719</lpage>
(<year>2012</year>).<pub-id pub-id-type="pmid">22281945</pub-id></mixed-citation>
      </ref>
      <ref id="R42">
        <label>42.</label>
        <mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>C-CC</given-names></name>, <name><surname>Park</surname><given-names>AY</given-names></name> &amp; <name><surname>Guan</surname><given-names>J-LL</given-names></name>
<article-title>In vitro scratch assay: a convenient and inexpensive method for
analysis of cell migration in vitro</article-title>. <source>Nat.
Protoc</source>. <volume>2</volume>,
<fpage>329</fpage>&#x2013;<lpage>333</lpage>
(<year>2007</year>).<pub-id pub-id-type="pmid">17406593</pub-id></mixed-citation>
      </ref>
      <ref id="R43">
        <label>43.</label>
        <mixed-citation publication-type="book"><name><surname>Westerfield</surname><given-names>M</given-names></name>
<chapter-title>The Zebrafish Book</chapter-title>
<source>A Guide for the
Laboratory Use of Zebrafish (Danio rerio)</source>, <edition>5th</edition>
Edition. <publisher-name>Univ. Oregon Press</publisher-name>
<publisher-loc>Eugene</publisher-loc> (<year>2007</year>).</mixed-citation>
      </ref>
      <ref id="R44">
        <label>44.</label>
        <mixed-citation publication-type="journal"><name><surname>Sander</surname><given-names>JD</given-names></name>, <name><surname>Zaback</surname><given-names>P</given-names></name>, <name><surname>Joung</surname><given-names>JK</given-names></name>, <name><surname>Voytas</surname><given-names>DF</given-names></name> &amp; <name><surname>Dobbs</surname><given-names>D</given-names></name>
<article-title>Zinc Finger Targeter (ZiFiT): An engineered zinc finger/target
site design tool</article-title>. <source>Nucleic Acids Res</source>.
<volume>35</volume>, <fpage>W599</fpage>&#x2013;<lpage>W605</lpage>
(<year>2007</year>).<pub-id pub-id-type="pmid">17526515</pub-id></mixed-citation>
      </ref>
      <ref id="R45">
        <label>45.</label>
        <mixed-citation publication-type="journal"><name><surname>Sander</surname><given-names>JD</given-names></name>
<etal/>
<article-title>ZiFiT (Zinc Finger Targeter): An updated zinc finger engineering
tool</article-title>. <source>Nucleic Acids Res</source>.
<volume>38</volume>, <fpage>W462</fpage>&#x2013;<lpage>W468</lpage>
(<year>2010</year>).<pub-id pub-id-type="pmid">20435679</pub-id></mixed-citation>
      </ref>
      <ref id="R46">
        <label>46.</label>
        <mixed-citation publication-type="journal"><name><surname>Jao</surname><given-names>L-E</given-names></name>, <name><surname>Wente</surname><given-names>SR</given-names></name> &amp; <name><surname>Chen</surname><given-names>W</given-names></name>
<article-title>Efficient multiplex biallelic zebrafish genome editing using a
CRISPR nuclease system</article-title>. <source>Proc. Natl. Acad. Sci. U. S.
A</source>
<volume>110</volume>, <fpage>13904</fpage>&#x2013;<lpage>9</lpage>
(<year>2013</year>).<pub-id pub-id-type="pmid">23918387</pub-id></mixed-citation>
      </ref>
      <ref id="R47">
        <label>47.</label>
        <mixed-citation publication-type="journal"><name><surname>Jaskula-Ranga</surname><given-names>V</given-names></name> &amp; <name><surname>Zack</surname><given-names>DJ</given-names></name>
<article-title>grID: A CRISPR-Cas9 guide RNA Database and Resource for
Genome-Editing</article-title>
<source>bioRxiv</source> (<year>2016</year>).</mixed-citation>
      </ref>
      <ref id="R48">
        <label>48.</label>
        <mixed-citation publication-type="journal"><name><surname>Ran</surname><given-names>FA</given-names></name>
<etal/>
<article-title>Genome engineering using the CRISPR-Cas9 system</article-title>.
<source>Nat. Protoc</source>
<volume>8</volume>, <fpage>2281</fpage>&#x2013;<lpage>2308</lpage>
(<year>2013</year>).<pub-id pub-id-type="pmid">24157548</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1.</label>
      <caption>
        <p id="P42">Identification of <italic>ROBO4</italic> variants segregating in
families with bicuspid aortic valve and aortic aneurysms. (<bold>a</bold>) Whole
exome sequencing (WES) revealed segregation of a heterozygous obligate splice
site mutation (g.124757628C&gt;A, c.2056+1G&gt;T) in a multigenerational
family. (<bold>b</bold>) cDNA amplicons spanning exons 11&#x2013;14 were
analyzed from patient (proband 1.II:4) and control fibroblasts. Sanger
sequencing confirmed skipping of exon 13 (108 base pair). (<bold>c</bold>) A
missense mutation (p.Arg64Cys) was observed in a small family. The missense
mutation resides at the Ig-like C2-type-1 (extracellular domain).
(<bold>d</bold>) Sequencing of 736 individuals with BAV/TAA and 376
controls. Eleven rare mutations (MAF&lt;0.1% with CADD&gt;20 or
MAF&lt;0.01%) were identified in 13/736 patients and one in 1/376 controls
(p.Asp510Val). AscAA: ascending aortic aneurysm, BAV: bicuspid aortic valve,
AoRA: aortic root aneurysm, AVS: aortic valve stenosis, ASD: atrial septal
defect, AVR: aortic valve replacement, NP: non-penetrant</p>
      </caption>
      <graphic xlink:href="nihms-1508198-f0001"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2.</label>
      <caption>
        <p id="P43">Evaluation of ascending aortic aneurysm tissue resected from patient
1.II:1, compared to an age- and sex-matched control. (<bold>a</bold>)
Immunofluorescent staining of CD31 (green), ROBO4 (red), and DAPI (blue) at the
intima-media interface. Arrows indicate ROBO4+ cells deep within the aortic
media. (<bold>b</bold>) Immunofluorescent staining of &#x237A;-SMA (green),
ROBO4 (red), and DAPI (blue) at the intima-media interface. (<bold>c</bold>)
Immunofluorescent staining of CD31 (green), ROBO4 (red), and DAPI (blue) at the
endothelial layer. (<bold>d</bold>) Immunofluorescent staining of albumin (red)
and DAPI (blue) at the luminal surface. (<bold>e</bold>) Histological staining
(H&amp;E, Masson&#x2019;s, and VVG) of patient and control ascending aortic
tissue. VVG: Verhoeff-Van Gieson</p>
      </caption>
      <graphic xlink:href="nihms-1508198-f0002"/>
    </fig>
    <fig id="F3" orientation="portrait" position="float">
      <label>Figure 3.</label>
      <caption>
        <p id="P44"><italic>ROBO4</italic> mutant alleles impair endothelial barrier
function. (<bold>a</bold>) HAECs were transfected with either co-plasmid
(control GFP plasmid), co-siRNA (control siRNA), OE-WT (overexpression of ROBO4
wild-type plasmid), siRNA (global ROBO4 knockdown), siRNA-Ex13 (ROBO4 knockdown
through targeting of exon 13), OE-SS (overexpression of ROBO4 cDNA plasmid
without exon 13), SS-alone (overexpression of ROBO4 cDNA plasmid without exon 13
plus silencing of endogenous ROBO4 using siRNA targeting exon 13), OE-R64C
(overexpression of ROBO4 cDNA plasmid with p.Arg64Cys) and
<italic>ROBO4</italic> mRNA expression was quantified. (<bold>b</bold>)
HAECs were cultured to confluency and a dextran permeability assay was used to
assess the integrity of the endothelial barrier. Error bars show mean &#xB1;
SE, <italic>n</italic> = 6. Asterisks signify significant differences per
one-way ANOVA with Tukey&#x2019;s Post-hoc (D.F.=7), *<italic>P</italic>
&lt; 0.05, **<italic>P</italic> &lt; 0.01. (<bold>c,d</bold>)
Immunofluorescent staining of tight junction protein ZO-1 (red), VE-cadherin
(green) and DAPI (blue). <italic>TJP1</italic> (encoding tight junction protein
ZO-1) expression and <italic>CDH5</italic> (encoding VE-cadherin) expression
were analyzed via qRT-PCR. For both <bold>a c and d</bold>, error bars show mean
&#xB1;SD, <italic>n</italic> = 6. Asterisks signify significant differences
per a one-way ANOVA with Tukey&#x2019;s Post-hoc (D.F.=7), *<italic>P</italic>
&lt; 0.05, **<italic>P</italic> &lt; 0.01.</p>
      </caption>
      <graphic xlink:href="nihms-1508198-f0003"/>
    </fig>
    <fig id="F4" orientation="portrait" position="float">
      <label>Figure 4.</label>
      <caption>
        <p id="P45"><italic>Robo4</italic> knockout causes aortic valve defects and aortic
aneurysm in mice. (<bold>a</bold>) Wild-type
(<italic>Robo4</italic><sup><italic>+/+</italic></sup>), heterozygous
(<italic>Robo4</italic><sup><italic>+/tm1Lex</italic></sup>), and knockout
(<italic>Robo4</italic><sup><italic>tm1Lex/tm1Lex</italic></sup>) mice were
aged to 20 weeks and the cardiovascular phenotype was determined. Aortic
dilatation was defined as a Z-score greater than two when compared to wild-type
male mice by echocardiography. Statistical differences per a one-tailed
Fisher&#x2019;s exact test, <italic>n</italic> = 112 total male and female mice,
<italic>P</italic> &lt; 0.05 was considered statistically significant.
(<bold>b</bold>) Representative parasternal long axis and pulsed-wave
Doppler images. Red arrows indicate a dilated segment of the ascending aorta.
The yellow arrow shows increased velocity of outflow across the aortic valve
during systole while the orange arrow shows regurgitant flow during diastole in
a <italic>Robo4</italic><sup><italic>tm1Lex/tm1Lex</italic></sup> mouse (similar
patterns were seen in the seven affected mice). (<bold>c</bold>) Gross and
histological examination of the aortic valve. Numbers refer to individual
commissures. AscAA: ascending aortic aneurysm, AoRA: aortic root aneurysm,
*abnormal aortic valve morphology including BAV, distal commissure fusion,
leaflet thickening, or quadricuspid aortic valve among mutant mice with flow
abnormalities by echocardiogram. Comparison is made to a representative sample
of wild-type mice. **pure bicommissural aortic valve that was definitively
evident by gross inspection. See <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 3</xref> for raw
data.</p>
      </caption>
      <graphic xlink:href="nihms-1508198-f0004"/>
    </fig>
    <fig id="F5" orientation="portrait" position="float">
      <label>Figure 5.</label>
      <caption>
        <p id="P46">Knock-in splice site mutation (c.2089+1G&gt;T;
<italic>Robo4</italic><sup><italic>Skip13</italic></sup>) causes aortic
valve defects and aortic aneurysm in mice. (<bold>a</bold>) Wild-type
(<italic>Robo4</italic><sup><italic>+/+</italic></sup>), heterozygous
(<italic>Robo4</italic><sup><italic>+/Skip13</italic></sup>), and homozygous
(<italic>Robo4</italic><sup><italic>Skip13/Skip13</italic></sup>) mice were
aged to 20 weeks and the cardiovascular phenotype was determined. Aortic
dilatation was defined as a Z-score greater than two when compared to wild-type
male mice by echocardiography. Significant differences per a one-tailed
Fisher&#x2019;s exact test, <italic>n</italic> = 106 total male mice,
<italic>P</italic> &lt; 0.05 was considered statistically significant.
(<bold>b</bold>) Representative parasternal long axis and pulsed-wave
Doppler images. Red arrows indicate a dilated segment of the aortic root. The
yellow arrow shows increased velocity of outflow across the aortic valve during
systole while the orange arrow shows regurgitant flow during diastole in a
<italic>Robo4</italic><sup><italic>Skip13</italic></sup> mouse (similar
patterns were seen in the five affected mice).. (<bold>c</bold>) Gross and
histological examination of the aortic valve. Numbers refer to individual
commissures. AscAA: ascending aortic aneurysm, AoRA: aortic root aneurysm.
*abnormal aortic valve morphology including BAV, distal commissure fusion,
leaflet thickening, or quadricuspid aortic valve among mutant mice with flow
abnormalities by echocardiogram. Comparison is made to a representative sample
of wild-type mice. **pure bicommissural aortic valve that was definitively
evident by gross inspection. See <xref rid="SD1" ref-type="supplementary-material">Supplementary Table 4</xref> for raw
data.</p>
      </caption>
      <graphic xlink:href="nihms-1508198-f0005"/>
    </fig>
    <table-wrap id="T1" position="float" orientation="landscape">
      <label>Table 1.</label>
      <caption>
        <p id="P47"><italic>ROBO4</italic> variants are more frequent in cases than in
controls</p>
      </caption>
      <table frame="void" rules="none">
        <colgroup span="1">
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
          <col align="left" valign="middle" span="1"/>
        </colgroup>
        <thead>
          <tr>
            <th colspan="9" align="left" valign="top" rowspan="1">
              <hr/>
            </th>
          </tr>
          <tr>
            <th align="center" valign="top" rowspan="1" colspan="1">WES Families</th>
            <th align="center" valign="top" rowspan="1" colspan="1">Variant</th>
            <th colspan="2" align="center" valign="top" rowspan="1">Verification</th>
            <th align="center" valign="top" rowspan="1" colspan="1">Domain</th>
            <th align="center" valign="top" rowspan="1" colspan="1">Fusion pattern</th>
            <th align="center" valign="top" rowspan="1" colspan="1">Family history</th>
            <th align="center" valign="top" rowspan="1" colspan="1">ExAC</th>
            <th align="center" valign="top" rowspan="1" colspan="1">CADD</th>
          </tr>
          <tr>
            <th colspan="9" align="left" valign="top" rowspan="1">
              <hr/>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">g.124757628C&gt;Ac.2056+1
G&gt;T</td>
            <td colspan="2" align="center" valign="top" rowspan="1">Sanger</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">R-N</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Absent</td>
            <td align="center" valign="top" rowspan="1" colspan="1">17.6</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.190C&gt;Tp.Arg64Cys</td>
            <td colspan="2" align="center" valign="top" rowspan="1">Sanger</td>
            <td align="center" valign="top" rowspan="1" colspan="1">IG-L 1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">L-R</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">19/98998</td>
            <td align="center" valign="top" rowspan="1" colspan="1">21.6</td>
          </tr>
          <tr>
            <td colspan="9" align="left" valign="top" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>WES Probands</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Variant</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Depth Allele 1</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Depth Allele 2</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Domain</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Fusion pattern</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Family history</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>ExAC</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>CADD</bold>
            </td>
          </tr>
          <tr>
            <td colspan="9" align="left" valign="top" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.283G&gt;Ap.Ala95Thr</td>
            <td align="center" valign="top" rowspan="1" colspan="1">7</td>
            <td align="center" valign="top" rowspan="1" colspan="1">6</td>
            <td align="center" valign="top" rowspan="1" colspan="1">IG-L 1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">R-N</td>
            <td align="center" valign="top" rowspan="1" colspan="1">No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5/117304</td>
            <td align="center" valign="top" rowspan="1" colspan="1">6.42</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.695C&gt;Tp.Thr232Met</td>
            <td align="center" valign="top" rowspan="1" colspan="1">42</td>
            <td align="center" valign="top" rowspan="1" colspan="1">36</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">R-L</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">10/121068</td>
            <td align="center" valign="top" rowspan="1" colspan="1">19.56</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.1233T&gt;Ap.His411Gln</td>
            <td align="center" valign="top" rowspan="1" colspan="1">31</td>
            <td align="center" valign="top" rowspan="1" colspan="1">30</td>
            <td align="center" valign="top" rowspan="1" colspan="1">FN2</td>
            <td align="center" valign="top" rowspan="1" colspan="1">R-N</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Absent</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.002</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.1702C&gt;Tp.Arg568Ter</td>
            <td align="center" valign="top" rowspan="1" colspan="1">43</td>
            <td align="center" valign="top" rowspan="1" colspan="1">49</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">R-L</td>
            <td align="center" valign="top" rowspan="1" colspan="1">No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">12/120920</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td colspan="9" align="left" valign="top" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Resequencing Probands</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Variant</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Depth Allele 1</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Depth Allele 2</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Domain</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Fusion pattern</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Family history</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>ExAC</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>CADD</bold>
            </td>
          </tr>
          <tr>
            <td colspan="9" align="left" valign="top" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.190C&gt;Tp.Arg64Cys</td>
            <td align="center" valign="top" rowspan="1" colspan="1">63</td>
            <td align="center" valign="top" rowspan="1" colspan="1">69</td>
            <td align="center" valign="top" rowspan="1" colspan="1">IG-L 1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">L-R</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">19/98998</td>
            <td align="center" valign="top" rowspan="1" colspan="1">21.6</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.740T&gt;Cp.Val247Ala</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1204</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1187</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">L-R</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1/121370</td>
            <td align="center" valign="top" rowspan="1" colspan="1">10.5</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.839A&gt;Cp.Tyr280Ser</td>
            <td align="center" valign="top" rowspan="1" colspan="1">590</td>
            <td align="center" valign="top" rowspan="1" colspan="1">469</td>
            <td align="center" valign="top" rowspan="1" colspan="1">FN1</td>
            <td align="center" valign="top" rowspan="1" colspan="1">R-N</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
            <td align="center" valign="top" rowspan="1" colspan="1">5/117546</td>
            <td align="center" valign="top" rowspan="1" colspan="1">22</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.1601_1614delp.Gly534Glufs*49</td>
            <td align="center" valign="top" rowspan="1" colspan="1">124</td>
            <td align="center" valign="top" rowspan="1" colspan="1">114</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Yes</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Absent</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.1864G&gt;Cp.Asp622His</td>
            <td align="center" valign="top" rowspan="1" colspan="1">767</td>
            <td align="center" valign="top" rowspan="1" colspan="1">721</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">L-R</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4/110004</td>
            <td align="center" valign="top" rowspan="1" colspan="1">21.3</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.1864G&gt;Cp.Asp622His</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1300</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1118</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">L-R</td>
            <td align="center" valign="top" rowspan="1" colspan="1">No</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4/110004</td>
            <td align="center" valign="top" rowspan="1" colspan="1">21.3</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>BAV/AscAA</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.2245_2246delinsCT p.Ala749Leu</td>
            <td align="center" valign="top" rowspan="1" colspan="1">195</td>
            <td align="center" valign="top" rowspan="1" colspan="1">173</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">R-N</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Absent</td>
            <td align="center" valign="top" rowspan="1" colspan="1">16.7</td>
          </tr>
          <tr>
            <td colspan="9" align="left" valign="top" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Controls</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Variant</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Depth Allele 1</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Depth Allele 2</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Domain</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Fusion pattern</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Family history</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>ExAC</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>CADD</bold>
            </td>
          </tr>
          <tr>
            <td colspan="9" align="left" valign="top" rowspan="1">
              <hr/>
            </td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <bold>Control</bold>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">c.1529A&gt;Tp.Asp510Val</td>
            <td align="center" valign="top" rowspan="1" colspan="1">69</td>
            <td align="center" valign="top" rowspan="1" colspan="1">51</td>
            <td align="center" valign="top" rowspan="1" colspan="1">/</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
            <td align="center" valign="top" rowspan="1" colspan="1">N/A</td>
            <td align="center" valign="top" rowspan="1" colspan="1">Absent</td>
            <td align="center" valign="top" rowspan="1" colspan="1">11.6</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>